Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000275261 | SCV000337608 | uncertain significance | not provided | 2017-12-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001082469 | SCV001100819 | likely benign | GNE myopathy; Sialuria | 2024-12-17 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004526657 | SCV005039768 | benign | not specified | 2024-03-19 | criteria provided, single submitter | clinical testing | Variant summary: GNE c.2097C>T alters a conserved nucleotide resulting in a synonymous change. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00016 in 251468 control chromosomes, predominantly at a frequency of 0.0014 within the African or African-American subpopulation in the gnomAD database. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 1.25 fold of the estimated maximal expected allele frequency for a pathogenic variant in GNE causing Inclusion Body Myopathy 2 phenotype (0.0011), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. To our knowledge, no occurrence of c.2097C>T in individuals affected with Inclusion Body Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 284820). Based on the evidence outlined above, the variant was classified as benign. |
Natera, |
RCV001273948 | SCV001457573 | uncertain significance | GNE myopathy | 2020-01-24 | no assertion criteria provided | clinical testing |